Consistent with significant reduction of PP2A activity in CD34+ progenitors from patients with Jak2V617F positive ET, PV, and MFI, treatment with Jak inhibitors may rescue PP2A activity through SET silencing (25). The gene discussed is PTPA; the disease is acquired polycythemia vera.